Drugs / Cytarabine arabinoside
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01056523 | Jan 2010 → Jan 2015 | acute myeloid leukemia | Jewish General Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02013167 Comparator | Jan 2014 → Dec 2015 | B-cell acute lymphoblastic leukemia | Amgen | Terminated | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytarabine arabinoside | “FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen” NCT02013167 ↗ |
| Route | Subcutaneous | “Cytarabine arabinoside will be given 20 mg sc bid days 1 to 10 of a 28 day cycle” NCT01056523 ↗ |